One-step synthesis of monodisperse transition metal core-shell nanoparticles with solid solution shells
US-9205410-B2 · Dec 8, 2015 · US
US10006908B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10006908-B2 |
| Application number | US-201615099129-A |
| Country | US |
| Kind code | B2 |
| Filing date | Apr 14, 2016 |
| Priority date | Feb 20, 2007 |
| Publication date | Jun 26, 2018 |
| Grant date | Jun 26, 2018 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The present invention is directed toward core-shell nanoparticles, each comprising a ligand-capped metal shell surrounding a plurality of discrete, nonconcentric, metal-containing cores. Methods of making and using these nanoparticles are also disclosed.
Opening claim text (preview).
What is claimed: 1. Core-shell nanoparticles, each core-shell nanoparticle comprising: a silver shell; a plurality of discrete, nonconcentric, iron oxide-containing cores, each core being within and surrounded by said silver shell; and a ligand cap over said silver shell. 2. The core-shell nanoparticles according to claim 1 , wherein the nanoparticles are present in a monodispersion with controlled diameters ranging from 5 nm to 100 nm. 3. The core-shell nanoparticles according to claim 1 , wherein the iron oxide-containing cores are magnetic, paramagnetic, or superparamagnetic. 4. The core-shell nanoparticles according to claim 1 wherein the iron oxide-containing core comprises a compound selected from the group consisting of Fe 3 O 4 and Fe 2 O 3 . 5. The core-shell nanoparticles according to claim 4 , wherein the iron oxide-containing core comprises Fe 2 O 3 . 6. The core-shell nanoparticles according to claim 4 , wherein the iron oxide-containing core comprises Fe 3 O 4 . 7. The core-shell nanoparticles according to claim 1 , wherein the ligand cap is selected from the group consisting of decanethiolate, oleylamine, oleic acid, acrylates, N,N-trimethyl(undecylmercapto)ammonium (TUA), tetrabutylammonium tetrafluoroborate (TBA), tetramethylammonium bromide (TMA), cetyltrimethylammonium bromide (CTAB), citrates, poly methacrylate, ascorbic acid, DNA, 2-mercaptopropionic acid (MPA), 3-mercaptopropionic acid (MPA), 11-mercaptoundecanoic acid (MUA), 10-mercaptodecane-1-sulfonic acid, 16-mercaptohexadecanoicacid, diimide, N-(2-mercaptopropionyl)glycine (tiopronin), 2-mercaptoethanol, 4-mercapto-1-butanol, dodecyl sulfate, amino acids, homocysteine, homocystine, cysteine, cystine, glutathione, mercaptobenzoic acid (MBA), Protein A, bovine serum albumin (BSA), and anti-rabbit-IgG (Ab). 8. The core-shell nanoparticles according to claim 7 , wherein the ligand cap is selected from the group consisting of decanethiolate, oleylamine, and oleic acid. 9. The core-shell nanoparticles according to claim 8 , wherein the ligand cap is decanethiolate. 10. The core-shell nanoparticles according to claim 8 , wherein the ligand cap is oleylamine. 11. The core-shell nanoparticles according to claim 8 wherein the ligand cap is oleic acid. 12. The core-shell nanoparticles according to claim 1 , wherein the ligand cap is tetraoctylammonium bromide. 13. The core-shell nanoparticles according to claim 1 further comprising: a first binding material bound to the ligand-capped shell. 14. The core-shell nanoparticles according to claim 13 , wherein the first binding material is selected from the group consisting of proteins, peptides, antibodies, and antigens. 15. The core-shell nanoparticles according to claim 1 , wherein the iron oxide-containing core comprises Fe 3 O 4 and the ligand cap is tetraoctylammonium bromide.
Combinations with other devices, not otherwise provided for · CPC title
Manufacture or treatment of nanostructures · CPC title
Making microcapsules or microballoons {(for medical preparations A61K9/50)} · CPC title
Metal or metal coated · CPC title
Magnetic particles · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.